Biogen

Predictability is mixed. Recurring specialty revenue exists across MS, SMA and rare diseases, but MS continues to erode from generics and biosimilars, and SMA faces oral/gene therapy competition. Alzheimer’s is a long secular opportunity, yet uptake is gated by diagnostic capacity, monitoring, registry requirements and competing labels.

The 2025 label and format expansions for Leqembi should gradually improve cadence, but quarterly variability is likely as systems adapt and international markets scale. Lupus and immunology programs could add multi-year growth vectors post-2026 readouts, but those are binary.

Geographic and policy risk is diversified but U.S. payers remain central for economics. Overall we expect low-to-mid single digit top-line trajectory near term, with upside optionality if Alzheimer’s and lupus adoption beat expectations.